Patents Assigned to BioSurface Engineering Technologies, Inc.
-
Patent number: 8796212Abstract: A composition comprising a synthetic growth factor analog comprising a non-growth factor heparin binding region, a linker and a sequence that binds specifically to a cell surface receptor and an osteoconductive material where the synthetic growth factor analog is attached to and can be released from the osteoconductive material and is an amplifier/co-activator of osteoinduction.Type: GrantFiled: July 19, 2011Date of Patent: August 5, 2014Assignee: BioSurface Engineering Technologies, Inc.Inventors: Paul O. Zamora, Brent Lee Atkinson, Xinhua Lin, Louis A. Pena
-
Publication number: 20120309694Abstract: The invention provides synthetic heparin-binding growth factor analogs having two peptide chains each branched from a branch moiety, such as trifunctional amino acid residues, the branch moieties separated by a first linker of from 3 to about 20 backbone atoms, which peptide chains bind a heparin-binding growth factor receptor and are covalently bound to a non-signaling peptide that includes a heparin-binding domain, preferably by a second linker, which may be a hydrophobic second linker. The synthetic heparin-binding growth factor analogs are useful as pharmaceutical agents, soluble biologics or as surface coatings for medical devices.Type: ApplicationFiled: April 24, 2012Publication date: December 6, 2012Applicant: BIOSURFACE ENGINEERING TECHNOLOGIES, INC.Inventors: Paul O. Zamora, Louis A. Pena, Xinhua Lin
-
Patent number: 8163717Abstract: The invention provides synthetic heparin-binding growth factor analogs having two peptide chains each branched from a branch moiety, such as trifunctional amino acid residues, the branch moieties separated by a first linker of from 3 to about 20 backbone atoms, which peptide chains bind a heparin-binding growth factor receptor and are covalently bound to a non-signaling peptide that includes a heparin-binding domain, preferably by a second linker, which may be a hydrophobic second linker. The synthetic heparin-binding growth factor analogs are useful as pharmaceutical agents, soluble biologics or as surface coatings for medical devices.Type: GrantFiled: October 6, 2009Date of Patent: April 24, 2012Assignee: BioSurface Engineering Technologies, Inc.Inventors: Paul O. Zamora, Louis A. Pena, Xinhua Lin
-
Patent number: 8101570Abstract: A heparin-binding growth factor (HBGF) analog having two substantially similar sequences (homodimeric sequences) branched from a single amino acid residue, where the sequences are analogs of a particular HBGF that binds to a heparin-binding growth factor receptor (HBGFR), or alternatively that bind to a HBGFR without being an analog of any particular HBGF. The homodimeric sequences may be derived from any portion of a HBGF. The synthetic HBGF analog may be an analog of a hormone, a cytokine, a lymphokine, a chemokine or an interleukin, and may bind to any HBGFR. Further provided are preparations for medical devices, pharmaceutical compositions and methods of using the same.Type: GrantFiled: May 24, 2010Date of Patent: January 24, 2012Assignee: BioSurface Engineering Technologies, Inc.Inventors: Kazuyuki Takahashi, Paul O. Zamora, Louis A. Pena, Xinhua Lin
-
Publication number: 20110305741Abstract: A composition comprising a synthetic growth factor analogue comprising a non-growth factor heparin binding region, a linker and a sequence that binds specifically to a cell surface receptor and an osteoconductive material where the synthetic growth factor analogue is attached to and can be released from the osteoconductive material and is an amplifier/co-activator of osteoinduction.Type: ApplicationFiled: July 19, 2011Publication date: December 15, 2011Applicant: BIOSURFACE ENGINEERING TECHNOLOGIES, INC.Inventors: Paul O. Zamora, Brent Lee Atkinson
-
Patent number: 7981862Abstract: A composition comprising a synthetic growth factor analogue comprising a non-growth factor heparin binding region, a linker and a sequence that binds specifically to a cell surface receptor and an osteoconductive material where the synthetic growth factor analogue is attached to and can be released from the osteoconductive material and is an amplifier/co-activator of osteoinduction.Type: GrantFiled: June 22, 2007Date of Patent: July 19, 2011Assignee: BioSurface Engineering Technologies, Inc.Inventors: Paul O. Zamora, Brent Lee Atkinson
-
Publication number: 20100298218Abstract: A heparin-binding growth factor (HBGF) analog having two substantially similar sequences (homodimeric sequences) branched from a single amino acid residue, where the sequences are analogs of a particular HBGF that binds to a heparin-binding growth factor receptor (HBGFR), or alternatively that bind to a HBGFR without being an analog of any particular HBGF. The homodimeric sequences may be derived from any portion of a HBGF. The synthetic HBGF analog may be an analog of a hormone, a cytokine, a lymphokine, a chemokine or an interleukin, and may bind to any HBGFR. Further provided are preparations for medical devices, pharmaceutical compositions and methods of using the same.Type: ApplicationFiled: May 24, 2010Publication date: November 25, 2010Applicant: BIOSURFACE ENGINEERING TECHNOLOGIES, INC.Inventors: Kazuyuki Takahashi, Paul O. Zamora, Louis A. Pena, Xinhua Lin
-
Patent number: 7820172Abstract: Multi-domain peptides including a heparin-binding peptide sequence covalently linked to a linker sequence, which linker sequence is covalently linked to a trifunctional amino acid residue forming a branch with two arms, with substantially similar (homodimeric) cellular attachment peptide sequences covalently linked, directly or through an intermediate, to each branch arm, where the sequences are cell binding analogs of or derived from laminin or a portion of laminin. Further provided are preparations for medical devices, pharmaceutical compositions and methods of using the same.Type: GrantFiled: June 1, 2007Date of Patent: October 26, 2010Assignee: BioSurface Engineering Technologies, Inc.Inventors: Paul O. Zamora, Kazuyuki Takahashi, Xinhua Lin
-
Publication number: 20100267650Abstract: The invention provides synthetic heparin-binding growth factor analogs having two peptide chains each branched from a branch moiety, such as trifunctional amino acid residues, the branch moieties separated by a first linker of from 3 to about 20 backbone atoms, which peptide chains bind a heparin-binding growth factor receptor and are covalently bound to a non-signaling peptide that includes a heparin-binding domain, preferably by a second linker, which may be a hydrophobic second linker. The synthetic heparin-binding growth factor analogs are useful as pharmaceutical agents, soluble biologics or as surface coatings for medical devices.Type: ApplicationFiled: October 6, 2009Publication date: October 21, 2010Applicant: BIOSURFACE ENGINEERING TECHNOLOGIES, INC.Inventors: PAUL O. ZAMORA, LOUIS A. PENA, XINHUA LIN
-
Patent number: 7700563Abstract: The invention provides synthetic heparin-binding growth factor analogs having at least one peptide chain, and preferably two peptide chains branched from a dipeptide branch moiety composed of two trifunctional amino acid residues, which peptide chain or chains bind a heparin-binding growth factor receptor and are covalently bound to a non-signaling peptide that includes a heparin-binding domain, preferably by a linker, which may be a hydrophobic linker. The synthetic heparin-binding growth factor analogs are useful as pharmaceutical agents, soluble biologics or as surface coatings for medical devices.Type: GrantFiled: August 19, 2003Date of Patent: April 20, 2010Assignees: BioSurface Engineering Technologies, Inc., Brookhaven Science AssociatesInventors: Louis A. Pena, Paul O. Zamora, Xinhua Lin, John D. Glass
-
Patent number: 7671012Abstract: Formulations, kits and methods for bone or cartilage repair, including treatment of osteogenic defects, including formulations of synthetic heparin-binding growth factor analogs, non-ionic polymers, gelling agents and calcium-containing agents.Type: GrantFiled: February 23, 2006Date of Patent: March 2, 2010Assignee: BioSurface Engineering Technologies, Inc.Inventors: Paul O. Zamora, Sarah Campion
-
Patent number: 7598224Abstract: The invention provides synthetic heparin-binding growth factor analogs having two peptide chains each branched from a branch moiety, such as trifunctional amino acid residues, the branch moieties separated by a first linker of from 3 to about 20 backbone atoms, which peptide chains bind a heparin-binding growth factor receptor and are covalently bound to a non-signaling peptide that includes a heparin-binding domain, preferably by a second linker, which may be a hydrophobic second linker. The synthetic heparin-binding growth factor analogs are useful as pharmaceutical agents, soluble biologics or as surface coatings for medical devices.Type: GrantFiled: February 24, 2005Date of Patent: October 6, 2009Assignee: BioSurface Engineering Technologies, Inc.Inventors: Paul O. Zamora, Louis A. Pena, Xinhua Lin
-
Publication number: 20090143566Abstract: The invention provides synthetic heparin-binding growth factor analogs of formulas I or II as given in the specification, having two peptide chains branched from a dipeptide branch moiety composed of at least one and preferably two trifunctional amino acid residues, which peptide chain or chains bind a heparin-binding growth factor receptor. The synthetic heparin-binding growth factor analogs are useful as pharmaceutical agents, soluble biologics or as surface coatings for medical devices.Type: ApplicationFiled: October 29, 2007Publication date: June 4, 2009Applicant: BioSurface Engineering Technologies, Inc.Inventors: Paul O. Zamora, Louis A. Pena, Xinhua Lin
-
Publication number: 20090111743Abstract: The present invention provides a heparin binding growth factor analog of any of formula I-VIII and methods and uses thereof.Type: ApplicationFiled: February 23, 2006Publication date: April 30, 2009Applicant: BioSurface Engineering Technologies, Inc.Inventor: Kazuyuki Takahashi
-
Patent number: 7482427Abstract: Compounds of the present invention of formula I and formula II are disclosed in the specification and wherein the compounds are modulators of Bone Morphogenic Protein activity. Compounds are synthetic peptides having a non-growth factor heparin binding region, a linker, and sequences that bind specifically to a receptor for Bone Morphogenic Protein. Uses of compounds of the present invention in the treatment of bone lesions, degenerative joint disease and to enhance bone formation are disclosed.Type: GrantFiled: February 22, 2005Date of Patent: January 27, 2009Assignees: BioSurface Engineering Technologies, Inc., Brookhaven Science AssociatesInventors: Paul O. Zamora, Louis A. Pena, Xinhua Lin, Kazuyuki Takahashi
-
Patent number: 7468210Abstract: A thromboresistant coating for a medical device, method of coating and coated medical device, the coating including an in situ cross-linked co-polymer of a cross-linkable biomolecule, preferably an adsorbable biomolecule such as a heparin activity biomolecule with at least one prosthetic hydrophobic unit, and a multifunctional crosslinking agent, such as a bis-variant of polyethylene glycol, polyethylene oxide, or polyethylene glycol, wherein the crosslinking is by means of covalent complexation through at least two functional groups of the multifunctional crosslinking agent.Type: GrantFiled: December 10, 2003Date of Patent: December 23, 2008Assignee: BioSurface Engineering Technologies, Inc.Inventor: Paul O. Zamora
-
Publication number: 20080227696Abstract: A heparin-binding growth factor (HBGF) analog having two substantially similar sequences (homodimeric sequences) branched from a single amino acid residue, where the sequences are analogs of a particular HBGF that binds to a heparin-binding growth factor receptor (HBGFR), or alternatively that bind to a HBGFR without being an analog of any particular HBGF. The homodimeric sequences may be derived from any portion of a HBGF. The synthetic HBGF analog may be an analog of a hormone, a cytokine, a lymphokine, a chemokine or an interleukin, and may bind to any HBGFR. Further provided are preparations for medical devices, pharmaceutical compositions and methods of using the same.Type: ApplicationFiled: February 21, 2006Publication date: September 18, 2008Applicant: BioSurface Engineering Technologies, Inc.Inventors: Kazuyuki Takahashi, Paul O. Zamora
-
Patent number: 7414028Abstract: The invention provides synthetic heparin-binding growth factor analogs of formulas I or II as given in the specification, having two peptide chains branched from a dipeptide branch moiety composed of at least one and preferably two trifunctional amino acid residues, which peptide chain or chains bind a heparin-binding growth factor receptor. The synthetic heparin-binding growth factor analogs are useful as pharmaceutical agents, soluble biologics or as surface coatings for medical devices.Type: GrantFiled: February 4, 2005Date of Patent: August 19, 2008Assignee: BioSurFace Engineering Technologies, Inc.Inventors: Paul O. Zamora, Louis A. Pena, Xinhua Lin
-
Publication number: 20080063622Abstract: A composition comprising a synthetic growth factor analogue comprising a non-growth factor heparin binding region, a linker and a sequence that binds specifically to a cell surface receptor and an osteoconductive material where the synthetic growth factor analogue is attached to and can be released from the osteoconductive material and is an amplifier/co-activator of osteoinduction.Type: ApplicationFiled: June 22, 2007Publication date: March 13, 2008Applicant: BIOSURFACE ENGINEERING TECHNOLOGIES, INC.Inventors: Paul Zamora, Brent Atkinson
-
Patent number: 7297343Abstract: A wound dressing, method of making, and method of use, utilizing a polymeric film having complexed thereto by hydrophobic interaction a construct including a polyanion covalently bonded to a hydrophobic prosthetic moiety, with one or more bioactive molecules directly complexed to the polyanion. The polyanion may be heparin or a heparin-activity molecule. The prosthetic group may include a hydrophobic silyl-containing moiety. Bioactive molecules include adhesive molecules, growth factor molecules, and therapeutic molecules, including antibiotics.Type: GrantFiled: October 10, 2003Date of Patent: November 20, 2007Assignee: BioSurface Engineering Technologies, Inc.Inventor: Paul O. Zamora